ALAllan Lemtudo

Allan Lemtudo

*This is an algorithmically generated author record based on publicly available information.

Allan Lemtudo has a total of 30 co-authors. Here are the top co-authors by number of shared publications:

  • John Waitumbi

    Basic Science Laboratory, Kenya Medical Research Institute (KEMRI)/Walter Reed Army Institute of Research-Africa, Kisumu, Kenya

    6 shared publications
  • Gathii Kimita

    Affiliation Walter Reed Army Institute of Research-Africa/Kenya Medical Research Institute, Kisumu, Kenya

    5 shared publications
  • George Awinda

    Affiliation Kenya Medical Research Institute/Walter Reed Army Institute of Research-Africa, Basic Science Laboratory, Kisumu, Kenya

    5 shared publications
  • Clement Masakhwe

    Affiliation Kenya Medical Research Institute/Walter Reed Army Institute of Research-Africa, Basic Science Laboratory, Kisumu, Kenya

    4 shared publications
  • Beth Mutai

    Affiliation Kenya Medical Research Institute/Walter Reed Army Institute of Research-Africa, Basic Science Laboratory, Kisumu, Kenya

    3 shared publications
  • Beth Mutai

    Kenya Medical Research Institute/US Army Medical Research Directorate–Africa/Kenya, Basic Science Laboratory. Off Kisumu - Kakamega Highway, Kisumu, Kenya

    3 shared publications

Latest Publications

  • Open Access

    SARS-CoV-2 and neutralizing antibody dynamics at a remote village in Kenya before widespread COVID-19 vaccine rollout

    by Esther Omuseni, Josphat Nyataya, Peter Sifuna, George Awinda, Allan Lemtudo, Clement Masakhwe, Beth Mutai, Geoffrey Maina, Simon Kariuki, John Waitumbi

    Given limited data on SARS‑CoV‑2 transmission and immunity in rural, low‑vaccine‑coverage settings, we evaluated infection rates and population‑level neutralizing antibody increase in a rural community in western Kenya. The study was conducted at the KEMRI/WRAIR-Africa Health Demographic Surveillance System that has a population of 160,000. Clusters of households that had representative demographics were identified and individuals invited to participate in six cross-sectional surveys that targeted 234 participants at each survey, two months apart, conducted between April 2021 and March 2022, during which time, the Alpha, Delta and Omicron waves dominated. At each survey, participants provided naso-pharyngeal samples for SARS-CoV-2 detection and serum for measuring neutralizing antibodies (NAbs) using surrogate virus neutralizing test which assessed inhibition of RBD–ACE2 binding. 69% (917/1329) of the participants were females. By RT-qPCR, SARS-CoV-2 increased from 3% (7/224) at survey one (April 2021) to 24% (55/229) by survey two (June 2021), and thereafter decreased to zero, only to rise to 10% (23/234) during the January 2022 Omicron wave. NAbs increased from 18% (40/224) at survey one to 86% (202/234) by end of the study. The quantity of NAbs rose from geometric mean of 0.42 U/mL at survey one to 9.4 U/mL by survey six. Females had higher NAbs (3.73U/mL, 95% CI), compared to 1.98 U/mL, 95% CI (p = 0.0146) for males. NAbs quantities increased with age: 2.1 U/mL for 60 years. The increase in population-level NAbs is consistent with widespread exposure to the virus during the study period. As caveat, causality of NAbs for the decline in SARS‑CoV‑2 infections cannot be inferred with confidence, because other factors such as the use of non‑pharmaceutical interventions and other individual-level variables were not measured.

  • Open Access

    Detection of zika virus disease caused by the Asian lineage of the zika virus at Kenya's Lamu island

    by Gathii Kimita, John Collins, Beth Mutai, Esther Omuseni, Clement Masakhwe, Stephen Ocholla, Allan Lemtudo, George Awinda, Rachel Githii, Gerald Kellar, et al.


  • Open Access

    Complete coding sequence of Rift Valley fever virus identified by metagenomic sequencing in patient with undifferentiated febrile illness at Marigat sub-district hospital, Kenya

    by Allan Lemtudo, Gathii Kimita, George Awinda, Beth Mutai, John Waitumbi

    We report on the complete coding sequence of Rift Valley Fever Virus inadvertently identified through metagenomics in a child with undifferentiated fever at Marigat sub-county hospital, Kenya. On phylogeny, the genome clustered with sequences obtained during the 2017 human outbreak in Uganda and the 2021 cattle outbreak in Kiambu, Kenya.

  • Open Access

    Temporal lineage replacements and dominance of imported variants of concern during the COVID-19 pandemic in Kenya

    by Gathii Kimita, Josphat Nyataya, Esther Omuseni, Faith Sigei, Alan Lemtudo, Eric Muthanje, Brian Andika, Rehema Liyai, Rachel Githii, Clement Masakwe, et al.

    Background: Kenya’s COVID-19 epidemic was seeded early in March 2020 and did not peak until early August 2020 (wave 1), late-November 2020 (wave 2), mid-April 2021 (wave 3), late August 2021 (wave 4), and mid-January 2022 (wave 5). Methods: Here, we present SARS-CoV-2 lineages associated with the five waves through analysis of 1034 genomes, which included 237 non-variants of concern and 797 variants of concern (VOC) that had increased transmissibility, disease severity or vaccine resistance. Results: In total 40 lineages were identified. The early European lineages (B.1 and B.1.1) were the first to be seeded. The B.1 lineage continued to expand and remained dominant, accounting for 60% (72/120) and 57% (45/79) in waves 1 and 2 respectively. Waves three, four and five respectively were dominated by VOCs that were distributed as follows: Alpha 58.5% (166/285), Delta 92.4% (327/354), Omicron 95.4% (188/197) and Beta at 4.2% (12/284) during wave 3 and 0.3% (1/354) during wave 4. Phylogenetic analysis suggests multiple introductions of variants from outside Kenya, more so during the first, third, fourth and fifth waves, as well as subsequent lineage diversification. Conclusions: The data highlights the importance of genome surveillance in determining circulating variants to aid interpretation of phenotypes such as transmissibility, virulence and/or resistance to therapeutics/vaccines.


  • Open Access

    COVID-19 mass testing and sequencing: Experiences from a laboratory in Western Kenya

    by John N. Waitumbi, Esther Omuseni, Josphat Nyataya, Clement Masakhwe, Faith Sigei, Allan Lemtudo, George Awinda, Eric Muthanje, Brian Andika, Rachel Githii, et al.

    Background: The Basic Science Laboratory (BSL) of the Kenya Medical Research Institute/Walter Reed Project in Kisumu, Kenya addressed mass testing challenges posed by the emergent coronavirus disease 2019 (COVID-19) in an environment of global supply shortages. Before COVID-19, the BSL had adequate resources for disease surveillance and was therefore designated as one of the testing centres for COVID-19. Intervention: By April 2020, the BSL had developed stringent safety procedures for receiving and mass testing potentially infectious nasal specimens. To accommodate increased demand, BSL personnel worked in units: nucleic acid extraction, polymerase chain reaction, and data and quality assurance checks. The BSL adopted procedures for tracking sample integrity and minimising cross-contamination. Lessons learnt: Between May 2020 and January 2022, the BSL tested 63 542 samples, of which 5375 (8.59%) were positive for COVID-19; 1034 genomes were generated by whole genome sequencing and deposited in the Global Initiative on Sharing All Influenza Data database to aid global tracking of viral lineages. At the height of the pandemic (August and November 2020, April and August 2021 and January 2022), the BSL was testing more than 500 samples daily, compared to 150 per month prior to COVID-19. An important lesson from the COVID-19 pandemic was the discovery of untapped resilience within BSL personnel that allowed adaptability when the situation demanded. Strict safety procedures and quality management that are often difficult to maintain became routine. Recommendations: A fundamental lesson to embrace is that there is no ‘one-size-fits-all’ approach and adaptability is the key to success.


  • Open Access

    A genomics dissection of Kenya’s COVID-19 waves: temporal lineage replacements and dominance of imported variants of concern

    by Gathii Kimita, Josphat Nyataya, Esther Omuseni, Faith Sigei, Allan Lemtudo, Eric Muthanje, Brian Andika, Rehema Liyai, Rachel Githii, Clement Masakhwe, et al.

    Kenya’s COVID-19 epidemic was slow to peak. It was seeded early in March 2020, and did not peak until late-July 2020 (wave 1), mid-November 2020 (wave 2) and late-March 2021 (wave 3). Here we present SARS-CoV-2 lineages associated with the three COVID-19 waves through analysis of 483 genomes, which included 167 Alpha (B.1.1.7), 57 Delta (B.1.617.2) and 12 Beta (B.1.351) variants of concerns (VOC) that dominated the third wave. In total, 35 lineages were identified. The early European lineages B.1 and B.1.1 were the first to be seeded in Kenya. The B.1 lineage continued to expand and remained the most dominant lineage accounting for 55.8% and 56.3% in waves 1 and 2 respectively. The alpha (B.1.1.7), delta (B.1.167.2) and beta (B.1.351) VOCs dominated in wave 3 at 59.0%, 20.1% and 4.2% respectively. Eventually, the delta variant took over at the tail end of wave 3 and at the time of going to press, it had become the major lineage in the whole country. Phylogenetic analysis suggested multiple introductions of variants from outside Kenya especially during the first and third wave. Phylogeny also highlighted local lineage diversification as local transmission events supervened. The data highlights the importance of genome surveillance in determining circulating variants to aid in public health interventions.